The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Based on the fact the company has spun so many words in the last 2 years and achieved nothing but a net spend of 12 million pounds. I can happily say a placing is on the way.
@marik I never said there was a placing, just highlighting the other facts of what a shocker this company has become.
you're right 2 months no placing, no commercial sales and no new contracts reported either. Still no sales figures from the DAM contract, and no they won't tell you what the minimum contract value is. I'm assuming it's low or they would have announced it as a positive. Last years sales %increases in CD4 we're against a backdrop of a year of COVID and no orders so p*ss poor.
Marik,
Nothing in today's RNS to do with FDA. If you refer to the presentation in December they already said it was cost-prohibitive. Another example of a big announcement in the summer on FDA and lack of due diligence of the process. Be careful out there, you can put lipstick on a pig!
Can people stop saying FDA EUA approval? That is not happening as Omega admitted themselves it's cost-prohibitive. So, please stop stating it's coming, as it's misleading.
As you were
Bet still stands mate
Maybe we need to ask what the sales and marketing director (Jag Grewal) has been up to for the last 2 years and how much did the rebrand cost?
If approval lands, it'll spike 40% and be completely sold into before dropping back. Not necessary to these levels. The damage is done. The directors are on a jolly to Dubai (nice bit of winter sun). Don't forget it's if approval lands. It's not a given.
Don't forget the revenue increase was based on the first year of Covid so it's not a great headline either. They just need to offer some words and direction. Even the chap from Lansdown has taken them off his Linked in, which speaks volumes to me.
Yes, 10% spread and 1% rise go figure. We're not off at all FFS
I said it before blinded by TV appearances and a big number on a piece of paper they never fully understood. Commercially inept and made lied a lot.
What I find amazing is 2 directors sold a shed load of shares on the 31st of March. When the contract pretty much expired on the 1st of April... How lucky was that?
No, it's not. The board is inept. Those numbers were always going to be up versus the first year in a pandemic. It's a **** show
So that will be for repackaging. We've been here before and the board have stated the packaging work turns a minimal profit.
It would help if Walbrook and Omega joined in and retweeted
You would but the BOD are all off until next week. Surprising, in what looks to be the biggest set of COVID cases in record over the next few days. You would assume if they had an ounce of commercials they'd be all over it. Oh yes it's Colin so BAU then!
Couldn't agree more. If anything it creates more questions. I don't trust the board anymore, there's a lack of transparency on commercial matters and nothing tangible has been answered.
I made this point yesterday. The company are supposed to be experts in this, so why is the submission not right the first time. Avct had dotted all their i's and crossed all the t's. Another show of incompetence. I believe Colin is way out of his depth, and as I have previously stated, got carried away by being on the TV and the big numbers from the DHSC.
I wouldn't hold your breath. Even the UK approvals documents were wrong initially, and they had to resubmit the information. I'm sorry, but the attention to detail is pretty poor for a company that specialises in this field. Look at the contract debacle, and even in the last presentation, the admittance they had to write down a load of inventory as it had gone out of date. You have to ask what has been going on at a management level for the last two years. I think the sky news interview and the big numbers went somewhat to their heads and now look where we are!
We're not pursuing the USA market. It was in the last presentation. It's cost-prohibitive to get a approval.